Whether the diagnosis is new (most commonly identified in early childhood) or you are navigating the medical aid system for haemophilia for the first time, this guide answers the key coverage and practical questions.
Does My Medical Aid Have to Cover This?
Yes. Haemophilia is a CDL condition. Factor replacement therapy is the CDL-minimum treatment standard. Your scheme cannot refuse to fund it, cannot impose an annual rand cap on the CDL benefit, and cannot limit the benefit based on age or duration of illness. This obligation applies to both Factor VIII (Haemophilia A) and Factor IX (Haemophilia B) replacement products.
What the CDL minimum does not automatically guarantee: - Extended half-life factor products (fewer injections; more convenient; more expensive) — may require exceptional-needs - Emicizumab (Hemlibra) — requires exceptional-needs authorisation from every scheme - A specific brand preference if the scheme has a designated supplier agreement for a different brand
Register for CDL as Early as Possible
For newly diagnosed children, CDL registration should be initiated immediately after diagnosis. For adults who have been managing privately without CDL registration, register now. The application requires:
- Haematologist's letter confirming diagnosis and severity classification
- Factor level assay result confirming severity (mild, moderate, or severe)
- ICD-10 code: D66 for Haemophilia A; D67 for Haemophilia B
- CDL registration form (obtainable from the scheme)
Once registered, factor concentrates are funded from the CDL benefit — not from the medical savings account. This matters significantly: the CDL benefit does not deplete; the MSA does.
Prophylaxis vs On-Demand: What Your Scheme Must Fund
This is the most common funding dispute in haemophilia management.
On-demand therapy: Factor concentrate given at the time of a bleed only. Appropriate for mild haemophilia and some moderate cases. For severe haemophilia, on-demand therapy results in accumulating joint damage over years because spontaneous bleeds occur before clotting is restored.
Prophylaxis: Scheduled, preventive factor infusions — typically 2–3 times per week for standard half-life products — maintain factor levels above the spontaneous bleed threshold. This is the evidence-based, internationally recognised standard of care for severe haemophilia. Prophylaxis prevents joint bleeds; joint bleeds prevented mean joint damage avoided; joint damage avoided means orthopaedic surgery avoided later.
If your scheme is funding on-demand therapy but your haematologist recommends prophylaxis for severe or moderate disease with a high bleed rate, ask your haematologist to submit a formal clinical motivation citing: - Factor activity level and severity classification - Annual bleed rate history - Clinical guidelines recommending prophylaxis for this severity (World Federation of Hemophilia, South African Haemophilia Foundation)
If declined on first submission, escalate through the scheme's internal appeals process. If still refused, the CMS can be engaged — the scheme has a weak position when denying the standard of care for a CDL condition.
Emicizumab (Hemlibra): How to Get It Funded
Emicizumab replaces the need for regular IV factor infusions in Haemophilia A. It is given subcutaneously once weekly, every two weeks, or monthly — a dramatic improvement in daily life, particularly for children. Monthly cost: approximately R60,000.
Every scheme requires an exceptional-needs application. Your haematologist must submit:
- Confirmed Haemophilia A diagnosis with factor activity level
- Current treatment regimen and annual bleed rate
- For inhibitor patients: inhibitor titre (Bethesda units) and prior bypass therapy history
- Clinical guidelines supporting emicizumab use (WFH 2020 guidelines)
- Weight-based dosing schedule
For patients with inhibitors, emicizumab is the preferred treatment under international guidelines — the appeal basis for a decline is very strong. For severe Haemophilia A without inhibitors, the case is built on clinical superiority and adherence benefit; approval timelines vary by scheme.
Orthopaedic Surgery: When Joints Are Damaged
Advanced haemophilic arthropathy may ultimately require total joint replacement — most commonly total knee replacement or ankle arthroplasty. Haemophilia surgery is complex because:
- High-dose perioperative factor replacement (or emicizumab cover) is required for 10–14 days post-procedure
- An orthopaedic surgeon experienced in haemophilia surgery is essential
- Perioperative factor cost alone can reach R200,000–R400,000
Pre-authorise explicitly and separately: obtain written authorisation for the surgical procedure and for the perioperative factor replacement protocol (quantities and days) in one coordinated process. Ask your scheme in writing: is perioperative factor covered under the CDL benefit, the in-hospital benefit, or as a separate pre-authorised line item? Get the answer before any surgery date is confirmed.
Inhibitor Development: Act Immediately
If inhibitor testing returns positive (Bethesda assay confirms inhibitor presence), contact your haematologist immediately and notify your scheme. Inhibitor development changes the treatment pathway completely and the cost profile dramatically. Request case management assignment from the scheme and initiate the emicizumab or bypass agent application without delay. Time matters — continued factor exposure with inhibitors present is ineffective and expensive.
Practical Checklist
| Action | Priority |
|---|---|
| Register for CDL (D66 or D67) | Immediate |
| Confirm factor concentrate supplier and brand coverage | This week |
| Confirm prophylaxis funding for severe disease | At next appointment |
| Begin emicizumab exceptional-needs application if indicated | Per haematologist guidance |
| Test for inhibitors per haematologist's schedule | Ongoing |
| Pre-authorise orthopaedic procedure + perioperative factor separately | Before any procedure |
| Confirm HTC designation and scheme requirements | This week |
Support Resources
South African Haemophilia Foundation (SAHF): www.sahf.org.za Patient support, advocacy, HTC network information, and educational resources for patients and families.
Talk to Eldon
Get help understanding your plan options →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).